Leerink Partners Reaffirms Outperform Rating for Aquestive Therapeutics (NASDAQ:AQST)

Aquestive Therapeutics (NASDAQ:AQST)‘s stock had its “outperform” rating reissued by Leerink Partners in a research report issued on Monday, Benzinga reports. They presently have a $12.00 price objective on the stock, up from their previous price objective of $10.00. Leerink Partners’ price target would suggest a potential upside of 154.24% from the company’s previous close.

Several other research firms have also recently weighed in on AQST. JMP Securities reissued a “market outperform” rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a report on Monday, August 12th. HC Wainwright increased their target price on Aquestive Therapeutics from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Aquestive Therapeutics presently has an average rating of “Buy” and an average target price of $8.67.

Aquestive Therapeutics Stock Down 5.6 %

AQST opened at $4.72 on Monday. The stock has a market cap of $429.70 million, a price-to-earnings ratio of -11.24 and a beta of 2.84. Aquestive Therapeutics has a 12-month low of $1.25 and a 12-month high of $6.23. The business has a 50 day moving average of $4.22 and a 200-day moving average of $3.70.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.08. The company had revenue of $20.10 million for the quarter, compared to the consensus estimate of $12.62 million. During the same period last year, the firm earned ($0.10) earnings per share. As a group, analysts expect that Aquestive Therapeutics will post -0.47 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Victory Capital Management Inc. acquired a new stake in shares of Aquestive Therapeutics in the second quarter valued at approximately $27,000. SG Americas Securities LLC acquired a new stake in Aquestive Therapeutics during the first quarter worth approximately $54,000. The Manufacturers Life Insurance Company bought a new position in Aquestive Therapeutics during the 2nd quarter worth $76,000. Financial Advocates Investment Management raised its holdings in Aquestive Therapeutics by 70.0% in the 2nd quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock valued at $88,000 after acquiring an additional 14,000 shares in the last quarter. Finally, Lazard Asset Management LLC raised its holdings in Aquestive Therapeutics by 115.5% in the 1st quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock valued at $124,000 after acquiring an additional 15,601 shares in the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.